Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
19.3M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
131M
-
Shares change
-
+533K
-
Total reported value, excl. options
-
$255M
-
Value change
-
+$1.52M
-
Put/Call ratio
-
1.08
-
Number of buys
-
54
-
Number of sells
-
-42
-
Price
-
$1.94
Significant Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) as of Q4 2023
130 filings reported holding LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share as of Q4 2023.
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 131M shares
.
Largest 10 shareholders include MWG Management Ltd. (20.2M shares), Orland Properties Ltd (15.1M shares), BlackRock Inc. (14.3M shares), VANGUARD GROUP INC (13.6M shares), Foresite Capital Management IV, LLC (8.33M shares), WuXi AppTec Co., Ltd. (8.18M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.64M shares), Alphabet Inc. (5.87M shares), GEODE CAPITAL MANAGEMENT, LLC (3.94M shares), and STATE STREET CORP (3.54M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.